NAMS - NewAmsterdam Pharma Company N.V.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.00
DETAILS
HIGH:
$55.00
LOW:
$37.00
MEDIAN:
$46.00
CONSENSUS:
$46.00
UPSIDE:
29.80%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 22.5 | 45.6 | 14.1 | 102.7 | 0 | 0 |
| Cost of Revenue | 0.1 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 22.4 | 45.6 | 14.1 | 102.7 | 0 | 0 |
| Operating Expenses | ||||||
| R&D Expenses | 141.8 | 151.4 | 159.4 | 86.7 | 29.0 | 4.9 |
| SG&A Expenses | 106.3 | 70.4 | 37.6 | 19.5 | 5.7 | 1.7 |
| Other Expenses | 0 | 0 | 0 | 0 | 0.3 | 0 |
| Operating Expenses | 248.1 | 221.9 | 197.1 | 106.3 | 35.0 | 6.6 |
| Operating Income | ||||||
| Operating Income | (225.7) | (176.3) | (183.0) | (3.6) | (35.0) | (6.6) |
| Interest Expense | 0 | 0 | 6.8 | 0.3 | 0.4 | 0 |
| Interest Income | 27.6 | 16.9 | 10.2 | 0 | 0 | 0.0 |
| Profitability | ||||||
| EBITDA | (242.3) | (241.5) | (176.9) | (22.3) | (41.4) | (6.6) |
| EBIT | (242.5) | (241.6) | (176.9) | (22.3) | (41.4) | (6.6) |
| Income Before Tax | (203.8) | (241.6) | (176.9) | (22.6) | (41.8) | (7.0) |
| Income Tax Expense | 0 | (0.0) | 0.0 | 0 | 0 | 0 |
| Net Income | (203.8) | (241.6) | (176.9) | (22.6) | (41.8) | (7.0) |
| Per Share Data | ||||||
| EPS (Basic) | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| EPS (Diluted) | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Shares Outstanding | 114.4 | 94.4 | 82.2 | 19.0 | 17.8 | 17.8 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Current Assets | ||||||
| Cash & Cash Equivalents | 490.0 | 771.7 | 340.4 | 467.7 | 60.4 | 1.4 |
| Short-Term Investments | 146.2 | 62.4 | 0 | 0 | 0 | 0 |
| Net Receivables | 23.2 | 21.3 | 1.9 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.3 | 0 | 0 | 2.1 | 4.9 | 0 |
| Total Current Assets | 675.7 | 863.4 | 346.8 | 478.0 | 67.0 | 1.9 |
| Non-Current Assets | ||||||
| Property, Plant & Equipment | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0.4 | 0.5 | 0.2 | 0.2 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 138.0 |
| Other Non-Current Assets | 92.6 | 0 | 0.0 | 0.2 | 0.8 | 0 |
| Total Non-Current Assets | 93.6 | 1.2 | 0.3 | 0.5 | 1.0 | 138.0 |
| Total Assets | 769.3 | 864.6 | 347.1 | 478.5 | 68.0 | 139.9 |
| Current Liabilities | ||||||
| Account Payables | 9.0 | 4.7 | 16.9 | 11.9 | 7.1 | 0.2 |
| Short-Term Debt | 0.1 | 0.2 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.0 | 6.0 | 8.9 | 0 | 0 | 0 |
| Other Current Liabilities | 72.7 | 91.0 | 16.0 | 18.0 | 0 | 0.1 |
| Total Current Liabilities | 85.8 | 106.9 | 49.9 | 36.1 | 11.2 | 0.2 |
| Non-Current Liabilities | ||||||
| Long-Term Debt | 0.1 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 7.8 | 12.3 | 0 | 12.2 |
| Total Non-Current Liabilities | 0.1 | 0.2 | 8.8 | 12.4 | 0.1 | 12.2 |
| Total Liabilities | 85.9 | 107.1 | 58.7 | 48.4 | 11.4 | 12.4 |
| Stockholders' Equity | ||||||
| Common Stock | 14.3 | 13.4 | 10.2 | 10.1 | 0.1 | 122.5 |
| Retained Earnings | (762.4) | 0 | (317.0) | (140.0) | (39.4) | 0.0 |
| Accumulated Other Comprehensive Income | 4.8 | 4.5 | 4.4 | 4.4 | 0.7 | 0 |
| Total Stockholders' Equity | 683.4 | 757.5 | 288.4 | 430.1 | 56.6 | 127.5 |
| Total Liabilities & Equity | 769.3 | 864.6 | 347.1 | 478.5 | 68.0 | 139.9 |
| Debt Metrics | ||||||
| Total Debt | 0.2 | 0.4 | 0.1 | 0.1 | 0.2 | 0 |
| Net Debt | (489.8) | (771.3) | (340.4) | (467.6) | (60.2) | (1.4) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 0 | (241.6) | (176.9) | (22.6) | (41.8) | (7.1) |
| Depreciation & Amortization | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stock-Based Compensation | 59.4 | 33.6 | 24.6 | 4.1 | 1.2 | 0 |
| Change in Working Capital | (7.9) | (32.7) | 5.9 | 10.4 | 4.5 | (0.6) |
| Other Non-Cash Items | (199.5) | 82.0 | 5.2 | 18.8 | 6.6 | 0.4 |
| Operating Cash Flow | (147.8) | (158.6) | (141.2) | 10.7 | (29.5) | (7.3) |
| Investing Activities | ||||||
| Capital Expenditure | (0.2) | (0.7) | (0.0) | (0.2) | (0.0) | (0.0) |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (296.7) | (62.2) | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 122.1 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (174.9) | (62.8) | (0.0) | (0.2) | (0.0) | (0.0) |
| Financing Activities | ||||||
| Net Debt Issuance | 0 | 0 | 0 | 0.7 | 0 | 13.9 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 14 | 0 | (5.8) | 0 | 0 |
| Financing Cash Flow | 29.5 | 659.5 | 8.9 | 391.9 | 84.7 | 13.9 |
| Cash Position | ||||||
| Net Change in Cash | (280.4) | 431.3 | (127.3) | 407.6 | 50.5 | 6.6 |
| Cash at Beginning | 771.7 | 340.4 | 467.7 | 60.1 | 9.6 | 3.1 |
| Cash at End | 491.3 | 771.7 | 340.4 | 467.7 | 60.1 | 9.7 |
| Free Cash Flow | (148.0) | (159.2) | (141.2) | 10.4 | (29.5) | (7.4) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 22.5 | 45.6 | 14.1 | 102.7 | 0 | 0 |
| Gross Profit | 22.4 | 45.6 | 14.1 | 102.7 | 0 | 0 |
| Operating Income | (225.7) | (176.3) | (183.0) | (3.6) | (35.0) | (6.6) |
| Net Income | (203.8) | (241.6) | (176.9) | (22.6) | (41.8) | (7.0) |
| EPS (Diluted) | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Balance Sheet | ||||||
| Cash & Equivalents | 490.0 | 771.7 | 340.4 | 467.7 | 60.4 | 1.4 |
| Total Assets | 769.3 | 864.6 | 347.1 | 478.5 | 68.0 | 139.9 |
| Total Debt | 0.2 | 0.4 | 0.1 | 0.1 | 0.2 | 0 |
| Stockholders' Equity | 683.4 | 757.5 | 288.4 | 430.1 | 56.6 | 127.5 |
| Cash Flow | ||||||
| Operating Cash Flow | (147.8) | (158.6) | (141.2) | 10.7 | (29.5) | (7.3) |
| Capital Expenditure | (0.2) | (0.7) | (0.0) | (0.2) | (0.0) | (0.0) |
| Free Cash Flow | (148.0) | (159.2) | (141.2) | 10.4 | (29.5) | (7.4) |